This is a preview of subscription content, log in via an institution to check access.
Reference
Castaneda-Orjuela CA, et al. Cost-Effectiveness Analysis of Introduction of Meningococcal Conjugate Vaccine in Colombia, 2011. 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PIN58, 18 May 2013.
Additional information
* The study received financial support from Novartis, Colombia.
Rights and permissions
About this article
Cite this article
Meningococcal conjugate vax not cost effective in Colombia. PharmacoEcon Outcomes News 680, 9 (2013). https://doi.org/10.1007/s40274-013-0473-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0473-8